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Abstract Thirty percent of ALS patients have a fron-
totemporal syndrome (FS), defined as behavioral changes
or cognitive impairment. Despite previous studies, there
are no firm conclusions on the effect of the FS on survival
and the use of non-invasive ventilation (NIV) in ALS. We
examined the effect of the FS on survival and the start and
duration of NIV in ALS. Behavioral changes were defined
as [22 points on the ALS-Frontotemporal-Dementia-
Questionnaire or C3 points on C2 items of the Neu-
ropsychiatric Inventory. Cognitive impairment was defined
as below the fifth percentile on C2 tests of executive
function, memory or language. Classic ALS was defined as
ALS without the frontotemporal syndrome. We performed
survival analyses from symptom onset and time from NIV
initiation, respectively, to death. The impact of the
explanatory variables on survival and NIV initiation were
examined using Cox proportional hazards models. We
included 110 ALS patients (76 men) with a mean age of
62 years. Median survival time was 4.3 years (95 % CI
3.53–5.13). Forty-seven patients (43 %) had an FS. Factors
associated with shorter survival were FS, bulbar onset,
older age at onset, short time to diagnosis and a C9orf72
repeat expansion. The adjusted hazard ratio (HR) for the FS
was 2.29 (95 % CI 1.44–3.65, p\ 0.001) in a multivariate
model. Patients with an FS had a shorter survival after NIV
initiation (adjusted HR 2.70, 95 % CI 1.04–4.67,
p = 0.04). In conclusion, there is an association between
the frontotemporal syndrome and poor survival in ALS,
which remains present after initiation of NIV.
Keywords Amyotrophic lateral sclerosis  Frontotemporal
syndrome  Cognitive impairment  Behavioral changes 
Survival  Non-invasive ventilation
Introduction
Thirty to 50 percent of amyotrophic lateral sclerosis (ALS)
patients have a frontotemporal syndrome, encompassing
behavioral changes and cognitive impairment
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[17, 20, 24, 27, 38]. In 8–10 % of ALS patients these
changes are more severe and fulfill the criteria for fron-
totemporal dementia (FTD) [24, 28]. The most frequent
encountered subtype of FTD is the behavioral variant
(bvFTD) albeit language variants of FTD may be found in
a minority of ALS patients. Median survival of ALS
patients is 3 years after symptom onset and the main cause
of death is respiratory failure. The disease course is neg-
atively influenced by older age at onset, early respiratory
dysfunction, bulbar onset, a short time to diagnosis and the
presence of a C9orf72 repeat expansion [6, 11, 12, 15, 34].
Previous studies suggested a negative effect of executive
dysfunction or neurobehavioral changes on survival of
ALS patients, although the use of general measures for
behavioral changes precluded firm conclusions in some of
them [10, 15, 18, 23, 26]. Indeed, the importance of a valid
assessment of the frontotemporal syndrome in ALS,
including the use of disease-specific measures has been
stressed [17]. This would allow for substantiating the pre-
sumed association between the frontotemporal syndrome
and survival in ALS [10, 15, 26]. The frontotemporal
syndrome, in particular the presence of behavioral changes,
was found to interfere with the initiation of life-prolonging
therapies, i.e., non-invasive ventilation (NIV). An analysis
of both cognitive and behavioral changes in patients who
used NIV might corroborate this association [10, 22, 26].
The first aim of this study was to investigate whether a
frontotemporal syndrome is an independent risk factor for
poor survival in ALS. Second, we aimed to gain insight
into the effect of the frontotemporal syndrome on NIV
initiation and duration in ALS patients.
Methods
Participants
In two of our previous studies, behavioral changes and
cognitive impairment were assessed in a total of 110 ALS
patients (n = 21 and n = 89, respectively) [29, 30]. ALS
patients in both studies were diagnosed with possible,
probable or definite ALS according to the El Escorial cri-
teria [5]. Concomitant FTD was diagnosed by the treating
neurologist, according to the Neary criteria [25]. Both
patient cohorts were recruited from the two tertiary referral
clinics for ALS in the Netherlands. Demographic and
clinical data were extracted from the databases, i.e., age,
years of education, site of onset (bulbar or limb), age at
onset, time to diagnosis, disease duration (time between
first symptom and study visit), vital capacity at inclusion
(percentage of the predicted value, as measured by hand-
held spirometry in the upright position), and score on the
Hospital Anxiety and Depression scale (HADS; a
maximum score of 42 indicates severe anxiety and
depression) [39]. Physical disability was measured with the
amyotrophic lateral sclerosis functional rating scale-re-
vised (ALSFRS-R; maximum score of 48 indicates no
physical disability) [8].
Data on the presence of the C9orf72 repeat expansion
were derived from the prospective population-based study
on motor neuron disease in the Netherlands [19]. DNA was
extracted from venous blood using standard protocols [37].
To detect large expanded repeats, a repeat primed PCR for
the C9ORF72 GGGGCC repeat was performed on genomic
DNA, as described previously [37]. The C9orf72 repeat
expansion was known in 89 (81 %) patients in the current
study. Time of death was checked in the Municipal Per-
sonal Records Database [14].
Standard protocol approvals and patient consents
The medical ethical committees of the hospitals approved
the studies. Written informed consent was obtained from
all participants at inclusion.
Assessment of behavior and cognition
In the first cohort (n = 21), behavioral changes were
assessed with the Neuropsychiatric Inventory (NPI)
[13, 30]. A score of C3 points on C2 items on the NPI has
been used by others as a cutoff for mild behavioral changes
in ALS [29, 35]. As described previously by others, we
carefully excluded behavioral changes that are more likely
due to physical disability (i.e., motor impairment mistaken
for apathy) or an appropriate reaction to their diagnosis
(e.g., comments about death). Cognitive functions were
assessed with a comprehensive neuropsychological exam-
ination. Neuropsychological tests were corrected for age,
education and dysarthria, as described previously [2, 30].
Cognitive impairment was defined as a score below the
fifth percentile on C2 tests of executive function, memory
or language, according to consensus criteria for cognitive
impairment in ALS [35].
In the second cohort (n = 89), behavioral changes were
assessed with the ALS-FTD-Questionnaire (ALS-FTD-Q).
The ALS-FTD-Q is a proxy-rated, disease-specific, vali-
dated instrument to detect behavioral changes in ALS [29].
The items of the questionnaire are based on a systematic
review of behavioral changes in motor neuron disease
patients with the behavioral variant of FTD [28]. A score of
[22 on the ALS-FTD-Q indicates mild behavioral changes
[29]. Cognitive functions in the second cohort were
assessed with the category fluency test, letter fluency test
and the Mini Mental State Examination (MMSE). Cogni-
tive impairment was defined as C2 impaired tests [35]. For
the fluency tests we used a cutoff below the fifth percentile
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of normative scores [33]. For the MMSE, an age and
education normative score was used which was adjusted for
the highest achievable score of individual patients; some
patients could not complete all items due to motor
impairment [16].
Classification of patients
Based on consensus criteria for the frontotemporal syn-
drome in ALS, we defined the following groups: classic
ALS, which is not associated with cognitive impairment or
behavioral changes, and ALS patients with a frontotem-
poral syndrome [35]. The frontotemporal syndrome was
defined as cognitive impairment, behavioral changes or
both. Patients with severe cognitive and behavioral changes
who fulfilled the criteria for the behavioral variant of FTD
were included in the group ‘‘ALS patients with a fron-
totemporal syndrome’’ [32].
Non-invasive ventilation
There are four Home Mechanical Ventilation centers in the
Netherlands from which data were derived on whether the
patient started NIV, and the dates on which the NIV was
initiated and ended. We also noted whether and when
tracheostomal ventilation was initiated.
Statistical analyses
Survival was calculated as time from symptom onset to
time of death or censoring date (February 24, 2015). As no
patients had tracheostomal ventilation, survival following
onset of NIV was calculated as time from onset of NIV to
time of death or censoring date (July 2014). We used
Kaplan–Meier survival analyses and compared the data
using the log-rank test. To examine which explanatory
variables should be included in the multivariate Cox pro-
portional hazards model, we performed univariate analyses
for the following factors: frontotemporal syndrome, bulbar
onset, age at onset, time to diagnosis, vital capacity, gender
and the presence of the C9orf72 repeat expansion.
Explanatory variables with a p value \0.25 in the uni-
variate analyses were included into a multivariate Cox
proportional hazards model (using the enter method).
Effect sizes were expressed in hazard ratios, statistical
uncertainty was expressed in 95 % confidence intervals.
The defined groups, classic ALS and ALS patients with a
frontotemporal syndrome, were compared using indepen-
dent t test, Pearson Chi-squared test and Fisher’s exact test.
All tests were two-tailed and statistical significance was set
at p\ 0.05. Statistical analyses were carried out using
SPSS version 21 (SPSS Inc., Chicago, IL).
Results
In total 110 ALS patients were included; 76 men and 34
women; 22 (20 %) ALS patients had bulbar onset. The
mean age was 62.0 years (SD 11.3; range 34–84). Median
time from symptom onset to diagnosis was 10 months
(range 2–90). The cognitive assessment was done at a
median disease duration after symptom onset of 3.3 years
(range 0.6–27.3). Forty-seven (43 %) ALS patients had a
frontotemporal syndrome, of whom 8 fulfilled criteria for
ALS-bvFTD. Sixteen (15 %) patients had only behavioral
changes, 18 (16 %) had cognitive impairment and 13
(12 %) had both (Fig. 1). None of the patients had a lan-
guage variant of FTD. There was no difference in occur-
rence of the frontotemporal syndrome between the two
cohorts (v2, p = 0.99) [29, 30]. Demographic and clinical
variables for the patient groups are shown in Table 1.
Survival analyses
At the time of analyses, 87 (79.1 %) patients had died. The
overall median survival time from symptom onset to death
was 4.3 years [95 % confidence interval (CI) 3.53–5.13].
Table 2 shows univariate analyses of risk factors for sur-
vival in all ALS patients. Frontotemporal syndrome, bulbar
onset, age at onset, time to diagnosis and the presence of
the C9orf72 repeat expansion had p values below 0.25 and
were included in the multivariate model.
Survival of ALS patients with a frontotemporal
syndrome
Median survival time was shorter in 47 patients with a
frontotemporal syndrome compared to 63 classic ALS
patients (3.8 years, 95 % CI 2.94–4.73 vs. 5.6 years, 95 %
CI 3.76–7.41, p = 0.001). The Kaplan–Meier curve is
shown in Fig. 2a. The impact effect of a frontotemporal
syndrome on survival was also observed in a multivariate
regression model adjusting for bulbar onset, age at onset,
Amyotrophic Lateral Sclerosis (n=110)
Behavioral 
changes (n=16) 
Cognitive 
impairment 
(n=18)
Both
(n=13)
Frontotemporal syndrome (n=47)
Only motor impairment (n=63)
Fig. 1 Venn diagram of the classification of amyotrophic lateral
sclerosis patients (n = 110)
J Neurol
123
time to diagnosis and the presence of the C9orf72 repeat
expansion (adjusted hazard ratio 2.29, 95 % CI 1.44–3.65,
p\ 0.001; Table 3).
Survival of ALS patients with behavioral changes
and/or cognitive impairment
ALS patients with both behavioral changes and cognitive
impairment had a median survival time of 3.4 years
(n = 13; 95 % CI 2.14–4.69, p = 0.01; Fig. 2b), compared
to 5.6 years in classic ALS. ALS patients with cognitive
impairment had a median survival time of 4.3 years
(n = 18; 4.3 years, 95 % CI 2.69–5.81, p = 0.012;
Fig. 2b). ALS patients with behavioral changes had a
median survival time of 3.8 years (n = 16; 95 % CI
2.94–4.81, p = 0.024; Fig. 2b). Multivariate analysis for
these subgroups was not performed, due to a small size.
Non-invasive ventilation
Forty-three patients (39 %) had used NIV of whom 29
(67 %) had classic ALS and 14 (33 %) had ALS with a
frontotemporal syndrome (v2, p = 0.08). Out of the 43
patients who had used ventilation, 8 (19 %) had bulbar
onset. All except two patients had used NIV until death.
Two patients used NIV 2 and 5 days and lived 11 and
18 days, respectively, following the termination of NIV.
None of the patients had tracheostomal ventilation.
Initiation of non-invasive ventilation
The median disease duration at NIV initiation was
3.9 years (range 0.5–8.2) for classic ALS and 3.1 years
(range 1.0–7.0) for ALS patients with a frontotemporal
syndrome (p[ 0.05). Patients with behavioral changes
initiated NIV less often compared to classic ALS patients
(2 out of 16; 12.5 % vs. 29 out of 63; 46 %, Fisher exact
p = 0.02). The proportion of ALS patients with cognitive
Table 1 Demographic and clinical characteristics of ALS patients
ALS-classic
(n = 63)
ALS-frontotemporal
syndrome (n = 47)
ALS-frontotemporal syndrome (n = 47)
ALS-cognitive
impairment (n = 18)
ALS-behavioral
changes (n = 16)
ALS-both
(n = 13)
Age at onset, years 56.5 (12.8) 61.6 (9.5)* 60.4 (9.1) 62.2 (8.9) 62.4 (11.2)
Male sex, n (%) 39 (61.9) 37 (78.7) 13 (72.2) 14 (87.5) 10 (76.9)
Bulbar onset, n (%) 6 (9.5) 16 (34.0)* 6 (33.3)* 4 (25.0) 6 (46.2)*
Time to diagnosis,
months (range)
13.6 (1–71) 14.4 (1–76) 14.2 (1–36) 10.9 (1–47) 19.1 (1–76)
ALSFRS-R 34.2 (8.8) 31.5 (8.3) 28.4 (9.4)* 33.4 (7.1) 33.4 (7.3)
Vital capacity (%) 84.9 (22.4) 77.9 (17.1) 75.8 (21.3) 82.6 (12.9) 74.9 (14.8)
C9orf72 repeat
expansion, n (%)
2 (3.2) 4 (8.5) 1 (5.6) 2 (12.5) 1 (7.7)
HADS-anxiety 10.2 (5.2) 10.5 (4.7) 10.9 (4.0) 9.1 (4.6) 11.8 (5.5)
HADS-depression 7.2 (3.7) 8.2 (3.7) 7.4 (2.4) 8.3 (4.1) 9.4 (4.6)
Education, years 13.9 (2.6) 14.1 (2.4) 14.6 (2.2) 13.3 (2.9) 14.4 (1.9)
NIV initiation, n (%) 29 (46.0) 14 (29.8) 8 (44.4) 2 (12.5)* 4 (30.8)
Values are mean (SD), unless stated otherwise. All groups are compared to the classic ALS group using an independent t test
ALS amyotrophic lateral sclerosis, ALSFRS-R ALS functional rating scale-revised (maximum score 48, indicates no disability), HADS Hospital
anxiety and depression scale, NIV non-invasive ventilation, y years
* p\ 0.05
Table 2 Univariate analysis of possible risk factors in all ALS
patients
Risk factor Hazard ratio 95 % CI p value
Bulbar onset 2.70 1.63–4.49 \0.001*
Age at onset 1.05 1.02–1.07 \0.001*
Time to diagnosis 0.97 0.95–0.99 0.001*
Vital capacity 1.00 0.99–1.01 0.544
Familial/sporadic ALS 1.25 0.64–2.42 0.515
Gender 1.23 0.77–1.96 0.385
C9orf72 repeat expansion 1.31 1.01–1.069 0.04*
Frontotemporal syndrome 2.09 1.36–3.21 0.001*
Behavioral changes 1.95 1.08–3.55 0.028*
Cognitive impairment 2.01 1.15–3.53 0.014*
Both 2.28 1.19–4.36 0.013*
ALS amyotrophic lateral sclerosis, CI confidence interval
* p\ 0.25; these variables were included into a multivariate Cox
proportional hazards model
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changes (with or without behavioral changes) that initiated
NIV did not differ from those with classic ALS.
Survival after non-invasive ventilation
ALS patients who had used NIV had a longer survival than
patients without NIV (median 6.0 years, 95 % CI 4.4–7.6
vs. 3.8 years 95 % CI 3.2–4.3, p = 0.03).
ALS patients with a frontotemporal syndrome had a
shorter survival after NIV initiation compared to those with
classic ALS (median 6 months, 95 % CI 0.00–18.9 vs.
31 months 95 % CI 19.9–43.0, p = 0.009; Fig. 3). The
impact effect of a frontotemporal syndrome on survival
(following NIV) was also observed in a multivariate
regression model adjusting for site of onset, age at onset,
time to diagnosis and the presence of the C9orf72 repeat
expansion (HR 2.7, 95 % CI 1.2–6.0, p = 0.02).
In an exploratory analysis, we analyzed the effect of the
frontotemporal syndrome on survival in the non-ventilated
group. Non-ventilated ALS patients with a frontotemporal
syndrome showed a trend to a shorter survival compared to
classic ALS patients without NIV (median 4.00 years,
95 % CI 3.43–3.82 vs. 3.59 years 95 % CI 2.55–4.62,
p = 0.06).
Fig. 2 a Kaplan–Meier analysis of the effect of frontotemporal
syndrome on ALS survival. Log-rank test for equality of survival
functions, p = 0.005. Black line ALS patients without frontotemporal
syndrome (n = 63); dotted line ALS with frontotemporal syndrome
(n = 47); ?: censored cases (n = 23). b Kaplan–Meier analysis of
the effect of cognitive impairment and/or behavioral changes on ALS
survival. Black line classic ALS patients, without frontotemporal
syndrome (n = 63); dotted line ALS with cognitive impairment
(n = 18, p = 0.012); dashed line ALS with behavioral changes
(n = 16, p = 0.02); dotted/dashed line ALS with both cognitive
impairment and behavioral changes (n = 13, p = 0.10); ?: censored
cases (n = 23); four patients (two censored) who had a survival time
of 15.6–29 years are not displayed in this figure
Table 3 Multivariate analysis for ALS patients with frontotemporal
syndrome on survival
Risk factor Hazard ratio 95 % CI p value
Age of onset 1.04 1.02–1.06 0.001
Bulbar onset 1.93 1.15–3.24 0.013
Extended C9orf72 repeat 1.54 1.17–2.03 0.002
Time to diagnosis 0.96 0.93–0.98 \0.001
Frontotemporal syndrome 2.29 1.44–3.65 \0.001
CI confidence interval
Fig. 3 Kaplan–Meier analysis of the effect of the frontotemporal
syndrome on ALS survival following initiation of NIV. Log-rank test
for equality of survival functions, p = 0.003. Black line ALS patients
without frontotemporal syndrome (n = 29); dotted line ALS with
frontotemporal syndrome (n = 14); ?: censored cases (n = 12)
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Discussion
In 110 patients with ALS, we examined the effect of the
presence of the frontotemporal syndrome on survival and
NIV initiation and duration.We showed that the concomitant
presence of the frontotemporal syndrome (behavioral chan-
ges, cognitive impairment or both) in patients with ALS is
associated with a significantly shorter survival independent
of other prognostic factors. We also found that the survival
after NIV initiation was significantly shorter in ALS patients
with a frontotemporal syndrome compared to classic ALS.
Thus, our findings suggest an association between the fron-
totemporal syndrome and poor survival in ALS patients,
which remains present following the initiation of NIV.
Known factors for a poor prognosis are older age at
onset, early respiratory dysfunction, bulbar onset, short
time to diagnosis and the presence of the C9orf72 repeat
expansion [6, 11, 12, 15, 34]. Early respiratory dysfunction
was not a relevant prognostic factor in our study, possibly
because the median vital capacity (percentage of predicted
value) of our patients was 84 % at inclusion [30].
Our study strengthens and extends findings from previ-
ous studies as our data robustly showed that not only
cognitive changes, but also behavioral changes negatively
affect survival in ALS [10, 15, 18, 26]. Importantly, for the
assessment of behavioral changes we used a disease-
specific instrument which has shown to prevent overesti-
mation of behavioral changes in ALS [29].
NIV is a life-prolonging therapy in ALS and, therefore,
an important variable to consider in survival studies in ALS
[4]. Reports on analyses of NIV use provide clues on
possible causes of reduced survival in ALS patients with a
frontotemporal syndrome [15, 26]. We showed that in
particular ALS patients with behavioral changes (and not
cognitive changes) less often initiated NIV, and that ALS
patients with a frontotemporal syndrome had a shorter
survival after NIV initiation compared to classic ALS
patients. Our data, due to relatively low numbers, do not
enable us to differentiate whether apathy, disinhibition or
dysexecutive behavior mediates this difference. An asso-
ciation between frontotemporal dysfunction and either the
initiation of NIV, or survival following NIV, has been
shown by others [10, 26]. Our study extends these findings
and suggests that a shorter survival due to a frontotemporal
syndrome can be explained by both a lower proportion of
ALS patients (with a frontotemporal syndrome) initiating
NIV, and a shorter survival of ALS patients with a fron-
totemporal syndrome, following NIV [10, 26]. Larger
cohorts are needed to confirm this association and other
issues. In particular, more data should be obtained on
compliance with NIV, the role of patients, proxies and
physicians in the decision-making process, and on end of
life practices in ALS patients with the frontotemporal
syndrome [9, 21, 31]. In addition, a study in a larger cohort
may elucidate the impact of different aspects of behavioral
changes in ALS (i.e., apathetic vs disinhibited type) [7].
In addition to the strengths of our study, some limita-
tions need to be addressed. The assessment of behavioral
changes and cognitive impairment differed slightly
between the two cohorts. However, no differences in out-
comes were shown between the cohorts. We included more
prevalent than incident patients, i.e., the disease duration
was more than 1 year in most patients. This is reflected by
a relatively long survival of the cohort, probably due to a
lower proportion of patients with a rapid disease course.
The cognitive testing in one cohort focused on executive
functions, which may have resulted in an underestimation
of cognitive deficits, because other cognitive domains can
be affected in ALS, even in the absence of executive def-
icits. As fluency is an important aspect of executive func-
tioning, the association of cognitive dysfunction with
survival in our study may have in part be driven by exec-
utive dysfunction, thus corroborating previous findings
from Elamin et al. [1, 3, 15, 36]. Due to small numbers we
were not able to perform multivariate analysis in the sub-
groups (i.e., patients with only cognitive impairment,
patients with only behavioral changes, and patients with
both). Finally, we were unable to retrieve sufficient data on
the initiation and duration of feeding by gastrostomy.
In conclusion, we have shown an effect of the fron-
totemporal syndrome on survival in ALS, which is in part
related to a shorter NIV use as compared to classic ALS
patients. These findings underline the importance of the
assessment of cognitive impairment and behavioral chan-
ges in ALS patients and contribute to a better under-
standing of prognostic factors in ALS.
Acknowledgments We would like to thank Laura Verweij from the
Center for Home Mechanical Ventilation Utrecht, Erik Smit from the
Center of Home Mechanical Ventilation Rotterdam for their help and
support with retrieving NIV data and Hermieneke Vergunst from the
University Medical Center Utrecht for her help retrieving the C9orf72
status.
Compliance with ethical standards
Conflicts of interest The authors report no disclosures.
Ethical standards The study was approved by the medical ethical
committees of the hospitals and was performed in accordance with the
ethical standards laid down in the 1964 Declaration of Helsinki and its
later amendments.
Informed consent Written informed consent was obtained from all
participants at inclusion.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
J Neurol
123
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Abdulla S, Machts J, Kaufmann J, Patrick K, Kollewe K, Dengler
R, Heinze HJ, Petri S, Vielhaber S, Nestor PJ (2014) Hip-
pocampal degeneration in patients with amyotrophic lateral
sclerosis. Neurobiol Aging 35:2639–2645
2. Beeldman E, Jaeger B, Raaphorst J, Seelen M, Veldink J, van den
Berg L, de Visser M, Schmand B (2014) The verbal fluency
index: Dutch normative data for cognitive testing in ALS.
Amyotroph Later Scler Frontotemp Degener 15:388–391
3. Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M,
Schmand BA, de Haan RJ (2015) The cognitive profile of ALS: a
systematic review and meta-analysis update. J Neurol Neurosurg
Psychiatry 87:611–619
4. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ,
Gibson GJ (2006) Effects of non-invasive ventilation on survival
and quality of life in patients with amyotrophic lateral sclerosis: a
randomised controlled trial. Lancet Neurol 5:140–147
5. Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial
revisited: revised criteria for the diagnosis of amyotrophic lateral
sclerosis. Amyotroph Later Scler 1:293–299
6. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B,
Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer
PM, O’Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG,
Pender N, Al-Chalabi A, Hardiman O (2012) Cognitive and
clinical characteristics of patients with amyotrophic lateral scle-
rosis carrying a C9orf72 repeat expansion: a population-based
cohort study. Lancet Neurol 11:232–240
7. Caga J, Turner MR, Hsieh S, Ahmed RM, Devenney E, Ramsey
E, Zoing MC, Mioshi E, Kiernan MC (2016) Apathy is associated
with poor prognosis in amyotrophic lateral sclerosis. Eur J Neurol
Off J Eur Fed Neurol Soc 23:891–897
8. Cedarbaum JM, Stambler N (1997) Performance of the Amy-
otrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in
multicenter clinical trials. J Neurol Sci 152(Suppl 1):S1–S9
9. Chio A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G
(2010) Tracheostomy in amyotrophic lateral sclerosis: a 10-year
population-based study in Italy. J Neurol Neurosurg Psychiatry
81:1141–1143
10. Chio A, Ilardi A, Cammarosano S, Moglia C, Montuschi A,
Calvo A (2012) Neurobehavioral dysfunction in ALS has a
negative effect on outcome and use of PEG and NIV. Neurology
78:1085–1089
11. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D,
Beghi E, Traynor BG (2009) Prognostic factors in ALS: a critical
review. Amyotroph Later Scler 10:310–323
12. Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A
(2015) Prognostic factors for the course of functional status of
patients with ALS: a systematic review. J Neurol 262:1407–1423
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi
DA, Gornbein J (1994) The Neuropsychiatric Inventory: com-
prehensive assessment of psychopathology in dementia. Neurol-
ogy 44:2308–2314
14. Database municipal personal records (2015) http://www.govern
ment.nl/issues/identification-documents/the-municipal-personal-
records-database. Accessed 24 Feb 2015
15. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N,
Hardiman O (2011) Executive dysfunction is a negative
prognostic indicator in patients with ALS without dementia.
Neurology 76:1263–1269
16. Folstein MF, Folstein SE, McHugh PR (1975) ‘‘Mini-mental
state’’. A practical method for grading the cognitive state of
patients for the clinician. J Psychiatr Res 12:189–198
17. Goldstein LH, Abrahams S (2013) Changes in cognition and
behaviour in amyotrophic lateral sclerosis: nature of impairment
and implications for assessment. Lancet Neurol 12:368–380
18. Hu WT, Shelnutt M, Wilson A, Yarab N, Kelly C, Grossman M,
Libon DJ, Khan J, Lah JJ, Levey AI, Glass J (2013) Behavior
matters—cognitive predictors of survival in amyotrophic lateral
sclerosis. PLoS One 8:e57584
19. Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS,
Schelhaas HJ, van der Kooi AJ, de Visser M, Veldink JH, van den
Berg LH (2011) Population based epidemiology of amyotrophic
lateral sclerosis using capture-recapture methodology. J Neurol
Neurosurg Psychiatry 82:1165–1170
20. Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges JR (2011)
How common are behavioural changes in amyotrophic lateral
sclerosis? Amyotroph Later Scler 12:45–51
21. Martin NH, Lawrence V, Murray J, Janssen A, Higginson I, Lyall
R, Burman R, Leigh PN, Al-Chalabi A, Goldstein LH (2016)
Decision making about gastrostomy and noninvasive ventilation
in amyotrophic lateral sclerosis. Qual Health Res 26:1366–1381
22. Merrilees J, Klapper J, Murphy J, Lomen-Hoerth C, Miller BL
(2010) Cognitive and behavioral challenges in caring for patients
with frontotemporal dementia and amyotrophic lateral sclerosis.
Amyotroph Later Scler 11:298–302
23. Mioshi E, Caga J, Lillo P, Hsieh S, Ramsey E, Devenney E,
Hornberger M, Hodges JR, Kiernan MC (2014) Neuropsychiatric
changes precede classic motor symptoms in ALS and do not
affect survival. Neurology 82:149–155
24. Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L,
Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S,
Canosa A, Chio A (2015) Cognitive correlates in amyotrophic
lateral sclerosis: a population-based study in Italy. J Neurol
Neurosurg Psychiatry 86:168–173
25. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S,
Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller
BL, Cummings J, Benson DF (1998) Frontotemporal lobar
degeneration: a consensus on clinical diagnostic criteria. Neu-
rology 51:1546–1554
26. Olney RK, Murphy J, Forshew D, Garwood E, Miller BL,
Langmore S, Kohn MA, Lomen-Hoerth C (2005) The effects of
executive and behavioral dysfunction on the course of ALS.
Neurology 65:1774–1777
27. Phukan J, Pender NP, Hardiman O (2007) Cognitive impairment
in amyotrophic lateral sclerosis. Lancet Neurol 6:994–1003
28. Raaphorst J, Beeldman E, de Visser M, de Haan RJ, Schmand B
(2012) A systematic review of behavioural changes in motor
neuron disease. Amyotroph Later Scler 13:493–501
29. Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WH,
Van den Berg LH, Pijnenburg YA, Grupstra HF, Weikamp JG,
Schelhaas HJ, Papma JM, van Swieten JC, de VM, de Haan RJ
(2012) The ALS-FTD-Q: a new screening tool for behavioral
disturbances in ALS. Neurology 79:1377–1383
30. Raaphorst J, de Visser M, van Tol MJ, Linssen WH, van der Kooi
AJ, de Haan RJ, Van den Berg LH, Schmand B (2011) Cognitive
dysfunction in lower motor neuron disease: executive and
memory deficits in progressive muscular atrophy. J Neurol
Neurosurg Psychiatry 82:170–175
31. Raaphorst J, Tuijp J, Verweij L, Westermann EJ, van der Kooi
AJ, Gaytant MA, van den Berg LH, de Visser M, Kampelmacher
MJ (2013) Treatment of respiratory impairment in patients with
motor neuron disease in the Netherlands: patient preference and
timing of referral. Eur J Neurol 20:1524–1530
J Neurol
123
32. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU,
Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW,
Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-
Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD,
Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black
SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J,
Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW,
Manes F, Grafman J, Cappa SF, Freedman M, Grossman M,
Miller BL (2011) Sensitivity of revised diagnostic criteria for the
behavioural variant of frontotemporal dementia. Brain
134:2456–2477
33. Schmand B, Groenink SC, van den Dungen M (2008) Letter
fluency: psychometric properties and Dutch normative data.
Tijdschr Gerontol Geriatr 39:64–76
34. Shoesmith CL, Findlater K, Rowe A, Strong MJ (2007) Prognosis
of amyotrophic lateral sclerosis with respiratory onset. J Neurol
Neurosurg Psychiatry 78:629–631
35. Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S,
Goldstein LH, Murphy J, Shoesmith C, Rosenfeld J, Leigh PN,
Bruijn L, Ince P, Figlewicz D (2009) Consensus criteria for the
diagnosis of frontotemporal cognitive and behavioural syndromes
in amyotrophic lateral sclerosis. Amyotroph Later Scler
10:131–146
36. Taylor LJ, Brown RG, Tsermentseli S, Al-Chalabi A, Shaw CE,
Ellis CM, Leigh PN, Goldstein LH (2013) Is language impair-
ment more common than executive dysfunction in amyotrophic
lateral sclerosis? J Neurol Neurosurg Psychiatry 84:494–498
37. van Rheenen W, van Blitterswijk M, Huisman MH, Vlam L, van
Doormaal PT, Seelen M, Medic J, Dooijes D, de Visser M, van
der Kooi AJ, Raaphorst J, Schelhaas HJ, van der Pol WL, Veldink
JH, van den Berg LH (2012) Hexanucleotide repeat expansions in
C9ORF72 in the spectrum of motor neuron diseases. Neurology
79:878–882
38. Woolley SC, Katz JS (2008) Cognitive and behavioral impair-
ment in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N
Am 19:607–617
39. Zigmond AS, Snaith RP (1983) The hospital anxiety and
depression scale. Acta Psychiatr Scand 67:361–370
J Neurol
123
